Potassium Ion

Potassium Ion

SCHEMBL3909671

N#CC1(CC(=O)[O-])CCCCC1.[K+]

nearest known ligand 0.37

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
CYP2C19 P33261 1/20 0.32
P2RX7 Q99572 1/20 0.32
USP2 O75604 1/20 0.31
LMNA P02545 1/20 0.31
CYP1A2 P05177 1/20 0.31
TSHR P16473 1/20 0.31
BLM P54132 1/20 0.31
CACNA2D1 P54289 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
DPP4 P27487 1/20 0.30
OPRM1 P35372 1/20 0.30
OPRL1 P41146 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8839908 0.96 ALDH1A1 (0.37) ALDH1A1CYP2C19P2RX7USP2LMNA
SCHEMBL3495245 0.79 CYP2C19 (0.48) ALDH1A1CYP2C19P2RX7USP2LMNA
SCHEMBL840651 0.79 CYP2C19 (0.48) ALDH1A1CYP2C19P2RX7USP2LMNA
SCHEMBL3909670 0.78 CYP2C19 (0.47) ALDH1A1CYP2C19P2RX7USP2LMNA
SCHEMBL5692544 0.78 ALDH1A1 (0.38) ALDH1A1CYP2C19P2RX7USP2LMNA
SCHEMBL2805815 0.77 CYP2C19 (0.45) ALDH1A1CYP2C19P2RX7USP2LMNA
SCHEMBL14744077 0.75 MCL1 (0.36) ALDH1A1CYP2C19P2RX7USP2LMNA
Potassium Ion SCHEMBL4756192 0.73
SCHEMBL2807409 0.72 HSD11B1 (0.41) ALDH1A1CYP2C19USP2LMNACYP1A2
SCHEMBL20724940 0.71 OPRM1 (0.34) ALDH1A1P2RX7OPRM1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5693845-A Cyanocycloalkylacetic acid and ester intermediates for preparing cyclic amino acid anticonvulsant compounds WARNER-LAMBERT COMPANY (US) 1997-12-02 US claimed
EP-0414262-B1 Process for the preparation of cyclic amino anticonvulsant compounds WARNER LAMBERT CO (US) 1994-11-30 EP claimed
US-5132451-A Process for cyclic amino acid anticonvulsant compounds WARNER-LAMBERT COMPANY (US) 1992-07-21 US claimed
EP-0414262-A2 Process for the preparation of cyclic amino anticonvulsant compounds WARNER-LAMBERT COMPANY (US) 1991-02-27 EP claimed
EP-2024324-A1 PROCESS FOR PREPARING GABAPENTIN Pfizer Science and Technology Ireland Limited (IE) 2009-02-18 EP disclosed
WO-2007129286-A1 PROCESS FOR PREPARING GABAPENTIN PFIZER SCIENCE AND TECHNOLOGY IRELAND LIMITED (IE) 2007-11-15 WO disclosed
US-5693845-A Cyanocycloalkylacetic acid and ester intermediates for preparing cyclic amino acid anticonvulsant compounds WARNER-LAMBERT COMPANY (US) 1997-12-02 US disclosed
EP-0414262-B1 Process for the preparation of cyclic amino anticonvulsant compounds WARNER LAMBERT CO (US) 1994-11-30 EP disclosed
US-5362883-A Process for cyclic amino acid anticonvulsant compounds WARNER-LAMBERT COMPANY (US) 1994-11-08 US disclosed
US-5319135-A Process for cyclic amino acid anticonvulsant compounds WARNER-LAMBERT COMPANY (US) 1994-06-07 US disclosed
US-5132451-A Process for cyclic amino acid anticonvulsant compounds WARNER-LAMBERT COMPANY (US) 1992-07-21 US disclosed
EP-0414262-A2 Process for the preparation of cyclic amino anticonvulsant compounds WARNER-LAMBERT COMPANY (US) 1991-02-27 EP disclosed